Literature DB >> 31174842

Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities.

Philamer C Calses1, James J Crawford2, Jennie R Lill3, Anwesha Dey4.   

Abstract

The Hippo pathway remains a central focus in both basic and translational research and is a key modulator of developmental biology. Dysregulation of the pathway is associated with a plethora of human cancers and there are multiple efforts to target key components of the pathway for disease intervention. In this review, we briefly highlight the latest research advances around the core components of the Hippo pathway in cancer. More specifically, we discuss several genetic aberrations of these factors as mechanisms for the development of cancers, including genetic amplification, deletion, and gene fusions. Additionally, we highlight the role of the Hippo pathway in cancer therapy resistance and tumor immunogenicity. Last, we summarize the ongoing efforts to target the pathway in cancers.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hippo pathway; TAZ; TEAD; YAP; cancer; drug development

Mesh:

Substances:

Year:  2019        PMID: 31174842     DOI: 10.1016/j.trecan.2019.04.001

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  76 in total

Review 1.  Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine.

Authors:  Anwesha Dey; Xaralabos Varelas; Kun-Liang Guan
Journal:  Nat Rev Drug Discov       Date:  2020-06-17       Impact factor: 84.694

Review 2.  Hippo pathway effectors YAP and TAZ and their association with skeletal muscle ageing.

Authors:  Iwan Setiawan; Ardo Sanjaya; Ronny Lesmana; Paul M Yen; Hanna Goenawan
Journal:  J Physiol Biochem       Date:  2021-01-26       Impact factor: 4.158

3.  The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma.

Authors:  Ayumi Kaneda; Toshihiro Seike; Tomohiro Danjo; Takahiro Nakajima; Nobumasa Otsubo; Daisuke Yamaguchi; Yoshiro Tsuji; Kaori Hamaguchi; Mai Yasunaga; Yoichi Nishiya; Michihiko Suzuki; Jun-Ichi Saito; Rie Yatsunami; Satoshi Nakamura; Yoshitaka Sekido; Kiyotoshi Mori
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

4.  Vestigial-like family member 3 (VGLL3), a cofactor for TEAD transcription factors, promotes cancer cell proliferation by activating the Hippo pathway.

Authors:  Naoto Hori; Kazuyuki Okada; Yuki Takakura; Hiroyuki Takano; Naoto Yamaguchi; Noritaka Yamaguchi
Journal:  J Biol Chem       Date:  2020-05-08       Impact factor: 5.157

5.  The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis.

Authors:  Xiaomeng Zhang; Lie Yang; Pacman Szeto; Gamze Kuser Abali; Youfang Zhang; Aishwarya Kulkarni; Kaushalya Amarasinghe; Jason Li; Ismael A Vergara; Ramyar Molania; Anthony T Papenfuss; Catriona McLean; Mark Shackleton; Kieran F Harvey
Journal:  Oncogene       Date:  2020-06-19       Impact factor: 9.867

6.  Targeting YAP Degradation by a Novel 1,2,4-Oxadiazole Derivative via Restoration of the Function of the Hippo Pathway.

Authors:  Eman M E Dokla; Chun-Sheng Fang; Po-Chen Chu; Chih-Shiang Chang; Khaled A M Abouzid; Ching S Chen
Journal:  ACS Med Chem Lett       Date:  2020-03-05       Impact factor: 4.345

7.  A gain-of-functional screen identifies the Hippo pathway as a central mediator of receptor tyrosine kinases during tumorigenesis.

Authors:  Taha Azad; Kazem Nouri; Helena J Janse van Rensburg; Sarah M Maritan; Liqing Wu; Yawei Hao; Tess Montminy; Jihang Yu; Prem Khanal; Lois M Mulligan; Xiaolong Yang
Journal:  Oncogene       Date:  2019-09-02       Impact factor: 9.867

Review 8.  Hippo Signaling in Embryogenesis and Development.

Authors:  Zhengming Wu; Kun-Liang Guan
Journal:  Trends Biochem Sci       Date:  2020-09-11       Impact factor: 13.807

9.  Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.

Authors:  Jack P Gleeson; Ines Nikolovski; Renzo Dinatale; Mark Zucker; Andrea Knezevic; Sujata Patil; Yasser Ged; Ritesh R Kotecha; Natalie Shapnik; Samuel Murray; Paul Russo; Jonathan Coleman; Chung Han Lee; Zsofia K Stadler; A Ari Hakimi; Darren R Feldman; Robert J Motzer; Ed Reznik; Martin H Voss; Ying-Bei Chen; Maria I Carlo
Journal:  Clin Cancer Res       Date:  2021-03-03       Impact factor: 12.531

Review 10.  The cross-talk between the Hippo signaling pathway and autophagy:implications on physiology and cancer.

Authors:  Fengyuan Tang; Gerhard Christofori
Journal:  Cell Cycle       Date:  2020-08-18       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.